Informace o publikaci

Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients

Autoři

SEDLAŘÍKOVÁ Lenka BEŠŠE Lenka KRYUKOV Fedor PELCOVA Jana ADAM Zdeněk POUR Luděk HÁJEK Roman ŠEVČÍKOVÁ Sabina

Rok publikování 2015
Druh Článek v odborném periodiku
Časopis / Zdroj Biomedical Papers of the Faculty of Medicine of Palacký University, Olomouc, Czech Republic
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
Doi http://dx.doi.org/10.5507/bp.2014.035
Obor Onkologie a hematologie
Klíčová slova multiple myeloma; minimal residual disease; tumor-specific marker; ASO PCR; RQ-PCR; IgH gene rearrangement
Popis Aim. Multiple myeloma (MM) is a malignant lymphoproliferative disease of terminally differentiated B lymphocytes, characterized by expansion of monoclonal plasma cells. It is the second most common hematological cancer in the world. The introduction of novel drugs is slowly turning MM into a chronic disease. The aim of treatment is hematological remission and eradication of clinical manifestation. Nevertheless, most MM patients eventually relapse. For this reason, research is focused on more accurate monitoring of remission and relapse by molecular biology techniques. One of these techniques is allele-specific PCR and quantitative real-time PCR based on specific detection of VDJ immunoglobulin heavy chain gene rearrangement of clonal cells. The hypervariable region of IgH rearrangement is used as a marker for detection of minimal residual disease (MRD) in MM as this sequence is used for allele-specific primers and probe design. This technique is a complementary tool for flow cytometry in MRD detection in MM. The aim of this study was to introduce detection of MRD by PCR in the Czech Republic. Results. We successfully introduced qualitative and quantitative detection of a tumor marker for MRD assessment of MM by PCR in our laboratory.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info